Dr. Vorobiof on Financial Toxicity in Oncology

Video

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Daniel A. Vorobiof, MD, chief medical director of Belong.Life, discusses financial toxicity in oncology.

Financial toxicity is an ongoing problem in the oncology space that has not been properly addressed to date, Vorobiof says.

In the United States, cancer is among the most expensive diseases to treat, along with heart disease, Vorobiof says. Moreover, financial toxicity is a global problem and cancer-related treatment expenses are continuing to rise.

Although financial toxicity may affect all patients differently, some health care professionals have been detached from the widespread burden financial toxicity can place on a patient with cancer, concludes Vorobiof.

Related Videos
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Debu Tripathy, MD
Changchun Deng, MD, PhD
Joaquim Bellmunt, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Parul N Barry, MD,
Ramez Kouzy, MD, MD Anderson
Bernard A. Fox, PhD
Bradley R. Corr, MD, associate professor, LeBert Suess Family Endowed Professor in Ovarian Cancer Research, gynecologic oncology team, the University of Colorado Anschutz Medical Campus